Introduction
Congenital myopathies (CMs) and congenital myopathic dystrophies (CMDs) are distinct groups of inherited diseases of muscle, which are genetically heterogeneous and manifest in early life or infancy. There are several main differences between the two categories of diseases: (1) the muscle histopathology in CMD is characterized by a dystrophic pattern (degenerative pattern with necrosis ± regeneration, extensive ®brosis), whereas no necrotic or degenerative changes are present in CM; (2) the creatine kinase level is elevated in CMD, whereas it is normal or slightly elevated in CM; (3) central nervous system (CNS) involvement is present in CMD.
Part I. Congenital myopathies
This group of myopathies, encompassing some wellknown`classic' conditions such as central core disease (CCD), nemaline myopathy, X-linked myotubular myopathy, and centronuclear myopathy, is continuously expanding and now comprises some 40 conditions. Classi®cation of these disorders has always been problematic. There may be marked phenotypic variation within families, some patients present in later life, and some patients have a more severe course than expected so the boundaries of some of the congenital myopathies are not clearly de®ned. Further insight into this group of disorders has been facilitated by molecular genetics and some degree of clarity has been established in recent years.
Central core disease
CCD was the ®rst congenital myopathy described [1] . It is characterized by the presence of well-demarcated round cores exclusively in type 1 ®bres [2] . A recent report however, highlights the fact that cores may be absent in affected individuals [3 . ]. As with many of the congenital myopathies, patients may be hypotonic at birth and have proximal muscle weakness with delayed developmental milestones. The course may be non-progressive or slowly progressive with frequent skeletal deformities such as congenital dislocation of the hips, pes cavus, kyphoscoliosis and ®nger¯exion deformities. The majority of patients remain fully active throughout life and severe motor de®cits are exceptional [4] .
The condition is inherited as an autosomal dominant trait (although sporadic cases have been reported) and diagnosis is often made only on muscle biopsy as some patients have very mild clinical abnormalities. The biopsy shows focal losses of oxidative enzyme activities in type 1 ®bres [2] .
CCD is closely associated with malignant hyperthermia (MH). Both conditions are associated with susceptibility to volatile anaesthetics and depolarizing muscle relaxants and both are primarily disorders of calcium regulation in skeletal muscle. The ryanodine receptor (RYR1) gene on chromosome 19q13.1 encodes the key channel which mediates calcium release in skeletal muscle during excitation±contraction coupling [5 . . ], and mutations in the gene are considered to account for susceptibility to MH in more than 50% of cases and in the majority of CCD cases. To date, over 20 missense mutations in the coding region of the RYR1 cDNA have been found to segregate with the MH trait, while a much smaller number of these mutations are associated with CCD (reviewed in [5 . . ]).
The majority of RYR1 mutations appear to be clustered in the N-terminal amino acid residues 35±614 (MH/ CCD region 1) and the centrally located residues 2163± 2458 (MH/CCD region 2) [5 . . ]. The only mutation identi®ed outside of these regions so far is a single mutation associated with a severe form of CCD in the highly conserved C-terminus of the gene [6] . All of the RYR1 mutations result in amino acid substitutions in the cytoplasmic portion of the protein, with the exception of the mutation in the C-terminus, which resides in the lumenal/transmembrane region. The MHS and CCD mutations produce RYR1 abnormalities that alter the channel for calcium inactivation and make the channel hyper and hyposensitive to activating and inactivating ligands, respectively [6] . Reports of new mutations in different populations will be important to enable estimation of the contributions of each gene mutation to the phenotype of MH and CCD [7 . ].
Nemaline myopathy
The congenital nemaline myopathies are characterized by the presence of numerous minute, rod-shaped structures called nemaline (`thread-like') bodies in the muscle ®bres which consist of proteins derived from the Z disc and thin ®lament. The clinical spectrum ranges from severe cases with antenatal or neonatal onset and early death to adult-onset cases with slow progression ]. In 1995, the ®rst genetic localization was reported in a large Australian family with an autosomal dominant form of nemaline myopathy and onset at junior school age with initially distal myopathy, caused by a mutation in the ®rst exon of the alpha-tropomyosin gene TPM3, on chromosome 1q21 [10] . The gene for slow tropomyosin, TPM3, was also later found to be homozygously mutated in one severe consanguineous case, with presumably recessive inheritance [11] . In the last 2 years, mutations were found in three other genes in nemaline myopathies: nebulin gene, on chromosome 2q21±2q22 [ The extent of genetic variation of autosomal recessive nemaline myopathy was reported recently [15] . Fortyone (of 45) families showed linkage to markers in the nebulin region. There was no indication of genetic heterogeneity for the typical form. In four families with more severe forms of nemaline myopathy, however, linkage to both the nebulin and the TPM3 locus was excluded, indicating that other genetic loci exist for this condition. Nemaline myopathy due to mutations in the alpha-actin gene are autosomal recessive, rarely dominant and frequently sporadic. These mutations generally cause severe disease but milder myopathies may also occur. Fifteen different missense mutations were found in 18 patients from 14 families [13] . De-novo mutations were identi®ed in seven sporadic probands [13] .
The most recently reported form was another recessive form of nemaline myopathy, which is common among the Amish population [ . . ] suggest that the occurrence of nemaline bodies could be a secondary feature of CCD, and that genetic studies on previously reported core/rod families might be targeted to the ryanodine receptor locus.
Multi-minicore disease (or multicore myopathy) originally referred to as multicore disease, multi-minicore disease (MmD) is a congenital myopathy characterized by the presence of multiple small zones of sarcomeric disorganization and lack of oxidative activity (`minicores') in muscle ®bres [18 . . ,19
. .
]. The differences between a`mini-core' and a`core' are that the former is not selective for a particular ®bre type and the`mini' refers to the fact that these cores never extend through the entire muscle ®bre length [ ]. No obvious differences were observed between normal and XLMTM myotubes. This model is consistent with the hypothesis that XLMTM might be intrinsically normal, suggesting the possible involvement of the motor nervous system in the late myogenic arrest and muscle maintenance defect seen in X-linked myotubular myopathy.
Centronuclear myopathy
This CM has often been previously confused with myotubular myopathy. It is now regognized as a distinct clinical and genetic entity. The genetic localization of autosomal dominant centronuclear myopathy is still unknown.
Congenital myopathy with intracytoplasmic inclusions
This is a heterogeneous group of congenital myopathies, the classi®cation of which remains unclear [29
. . ]. Abnormal inclusions within muscle ®bres may derive from pre-existing structures. This group includes nemaline or rod myopathy when rods are seen within both the sarcoplasm (as described above) and the nuclei of the muscle ®bres. . . ]. Actin-related myopathy (actinopathy) is also a surplus protein myopathy and recent demonstration of actin (previously recognized as thin ®laments) in myo®bres has been supported by genetic studies which revealed several missense mutations in the actin gene [13] . Thus, mutations in the skeletal muscle alpha-actin gene are associated with two different myopathies:`congenital myopathy with excess of thin ®laments' and nemaline myopathy, described earlier.
Hyaline body myopathy is another candidate for this category. Hyaline bodies are rare subsarcolemmal aggregates in type 1 ®bres of the skeletal muscle, which lack reactivity for glycogen and oxidative enzymes [34 . . ]. The histopathology is marked by patches of granular material within muscle ®bres, which is unlike that of the desmin-related myopathy. It occurs in children and adults, and in familial and sporadic forms.
An autosomal-dominant form presents with slowly progressive muscle weakness and atrophy in a scapuloperoneal distribution [35] . The hyaline bodies may be products of degeneration of the myosin heavy chain (slow) [35] .
In a subgroup of inclusion body myopathies is a second category in which the inclusions are, as yet, of unexplained origin. Few details have been published about these disorders in recent years but they include the following:
(1) Reducing body myopathy: originally described in two severely hypotonic infants, this condition has a wide variation in age of onset with the most recent reported case in an adult female Other congenital myopathies
Other recently described but as yet ill-de®ned CMs include the following:
(1) Congenital myopathy with muscle spindle excess: a single case report [43 . ] suggested the possibility of an unusual form of CM with a syndromic association in a hypotonic infant with arthrogryposis, trial tachycardia, and an abdominal neuroblastoma.
(2) Apoptotic myopathy: a case of CM with apoptotic process was reported [44 . ]. The most striking pathological finding was the presence of many condensed and fragmented muscle nuclei. (3) Myopathy with hexagonally cross-linked tubular arrays: a slowly progressive myopathy with unique crystalloid inclusions in type 2 fibres in a father and his son, as well as another, unrelated individual was described [45] . The inclusions were unrelated to any normal cell component. This may be a new CM with characteristic intracytoplasmic inclusions, occurring sporadically or with an autosomal dominant pattern of inheritance.
Part II. Congenital muscular dystrophy
The CMDs are a heterogeneous group of autosomal recessive myopathies characterized by early onset hypotonia, muscle weakness, joint contractures, and a dystrophic pattern at muscle biopsy. A ®rst category of CMD is not associated with intellectual impairment or with major structural brain abnormalities. In 1994, Tome Â et al. [46] demonstrated a de®ciency of merosin in about half of the biopsies of this group of patients and, shortly after, the gene encoding the laminin a2 chain of merosin was identi®ed on chromosome 6q2 [47, 48] . The laminin 2 (formerly merosin) isoform, composed of the a2 heavy chain assembled with b1 and g1 light chains, is speci®cally expressed in the basal lamina of striated muscle and peripheral nerve [49] . Patients are homozygotes or compound heterozygotes and various mutations were found (deletions, insertion, deletion± insertion, non-sense, very rarely missense), located both in the carboxyl terminus G domain and in the rod-like domains of the protein [50] ; most of them result in stop codons. Pre-natal diagnosis is now available [51] . The merosin-de®cient group is relatively homogeneous, but milder CMD cases were reported with partial merosin de®ciency and internally deleted laminin a2 chain [52] . Other patients with`pure' CMD are merosin nonde®cient or merosin positive. Overall, the merosin nonde®cient cases are less severe than merosin positive cases and exhibit marked clinical heterogeneity. Recently, a new locus was found on chromosome 1p35±36 coding for a peculiar form of merosin positive CMD with early rigidity of the spine [53] . The other merosin positive cases are not yet genetically characterized. Mental retardation and structural brain changes are a major feature of several groups of CMD. Fukuyama type (FCMD), affecting the Japanese population, was the ®rst CMD localized in 1993, on chromosome 9q31 [54] . In 1998, the gene responsible for FCMD was identi®ed, coding for a novel 461 amino acid protein, termed fukutin. Most FCMD-bearing chromosomes have been derived from a single ancestral founder, whose mutation consisted of a 3 kb retrotransposal insertion in the 3' non-coding region of the fukutin gene [55] . The muscle eye brain (MEB) disease, found mainly in Finland, was assigned to chromosome 1p32±34 in 1999 [56] . ]. The severity of CMD may depend on isoform expression of the laminin a2 gene which has been recently described [60 . ]. In a patient with severe CMD who was a compound heterozygote for two non-sense mutations in the a2 laminin gene (one of them located in the spliced region), it was suggested that the severe phenotype may be due to over-expression of the alternatively spliced isoform which could impair the chain assembly of merosin [60 . ].
The dy/dy mouse is genotypically and phenotypically similar to humans with CMD due to a de®ciency of laminin a2. A high-resolution magnetic resonance imaging (MRI) study of the dy/dy mouse brain was performed on homozygous and heterozygous mice [61 .
]. No cerebral MRI abnormalities were found. The explanation for this result could be`technical', due to particular imaging features in animals. Another hypothesis is that white matter abnormalities only develop later in the disease.
Pure congenital myopathic dystrophy unlinked to a2 laminin gene Novel variants of pure CMD not linked to the a2 laminin gene have been reported. A form of CMD with secondary merosin de®ciency has been assigned to chromosome 1q42 in two families, one consanguineous family from the United Emirates, the second, nonconsanguineous family from Germany [62
. . ]. Brain MRI studies and intellect were normal. Muscle involvement was characterized by proximal girdle weakness, generalized muscle hypertrophy, rigidity of the spine and severe diaphragmatic involvement in one family. This novel variant was called CMD1B (CMD1A representing CMD with primary merosin de®ciency). The primary defect may be in the interaction between the basal lamina and the sarcolemma. In two Scottish siblings with a severe CMD similar to that observed in the 6q-linked merosin de®cient cases, but in whom MRI, nerve conduction and cognitive development were normal, linkage studies excluded all the known loci for CMD ( . . ]. All but a few patients carried at least one chromosome bearing the ancestral founder mutation consisting of a 3 kb retrotransposon insertion. The frequency of severe phenotypes, including Walker±Warburg syndrome-like cases (hydrocephalus, microphthalmia) was signi®cantly higher among compound heterozygotes carrying the founder mutation and another mutation than it was in the probands homozygous for the 3 kb transposon. Novel non-founder mutations were also found.
Expression of fukutin has been studied in cortex and in cerebellum [67
. . ]. On Western blotting, the fukutin protein was found to be a 60 kd band protein that is abundantly expressed in fetal brains but undetectable in post-natal brains. This band was negligible in the brains of FCMD fetuses. The localization of the fukutin assayed by immunohistochemistry revealed its presence in Cajal±Retzius cells, the subpial granular layer, the neuropils of the marginal zone, the cortical plate neurons, and the ventricular neuroepithelium of the fetal cerebrum. In the fetal cerebellum, fukutin was localized to the external granule cell layer, molecular layer, purkinje cells, and some internal granular cells. The immunoreactivity was markedly reduced in postnatal brain, as well as in FCMD cerebrum at 23 gestational weeks. Thus, it is likely that fukutin protein plays a critical role in the regulation of neuronal migration in the fetal cerebrum and cerebellum.
Walker±Warburg syndrome is genetically distinct from Fukuyama type congenital muscular dystrophy [68 . ] but they may be dif®cult to distinguish clinically. The absence of FCMD mutations is a crucial point, allowing differentiation of Walker±Warburg syndrome from severe FCMD cases.
Congenital muscular dystrophy with mental retardation unlinked to laminin a2, Fukuyama-type congenital muscular dystrophy and muscle eye brain locus
There is marked heterogeneity of classic congenital muscular dystrophy with CNS involvement described, which is unlinked to the laminin a2, FCMD and MEB loci. One group reported four Italian cases aged 3±13 years from three non-consanguineous families, who presented in addition to severe mental retardation, microcephaly, and calf hypertrophy 
Conclusions
Much progress has been made in the last year towards clarifying the classi®cation of CMs and CMDs. Possible new forms of myopathy have been described and the clinical and genetic heterogeneity of many of these conditions has been underlined. As with the later-onset muscular dystrophies, it should not be too long before the determination of the underlying genetic defects in all of these conditions is complete. This should enable physicians to counsel patients and their families more precisely than has been the case up to now. 
